

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Synribo (omacetaxine mepesuccinate)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Synribo (omacetaxine mepesuccinate)

APPROVAL CRITERIA

Requests for Synribo (omacetaxine mepesuccinate) may be approved if the following criteria are met:

- I. Individual has a diagnosis of chronic or accelerated phase chronic myeloid leukemia (CML); **AND**
- II. Individual has resistance and/or intolerance to TWO or more tyrosine kinase inhibitors (TKI);

OR

- III. Individual has a diagnosis of CML and is using as monotherapy (NCCN 2A); **AND**
 - A. Individual is receiving for post-allogenic stem cell transplant follow-up therapy with molecular relapse (BCR-ABL1 transcript) following complete cytogenetic response (CCyR) (NCCN 2A); **OR**
 - B. Individual is receiving for post-allogenic stem cell transplant follow-up therapy with relapse or those who are not in CCyR (NCCN 2A); **OR**
 - C. Individual has T3151 mutation positive disease (NCCN 2A).

Note: Tyrosine kinase inhibitors include Gleevec (imatinib), Tassigna (dasatinib), Sprycel (nilotinib), Bosulif (bosutinib), Iclusig (ponatinib)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 4/2018.

DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.